Key Demographics and Behaviors for Consumers Using Search Engines for Online Health and Pharma Info

Manhattan ResearchConsumers are performing pharma-related searches at more points along the treatment continuum, according to pharmaceutical and healthcare market research company Manhattan Research. Consumers are most likely to use search engines for pharma information when they have symptoms for a condition, after receiving a diagnosis from a physician, and before beginning to take a new prescription. The findings come from ePharma Consumer® v8.0, the company's latest market research and strategic advisory service focused on how consumers find and use pharmaceutical resources online.

The study also looks at search behaviors for a variety of demographic and condition groups. While Google is the most popular search engine among those online for pharma information as a whole, use of and behavior on Google, Yahoo! Search, MSN Search, AOL Search, and other search engines vary by age, patient condition, and other factors.

"Today's savvy health consumers rely on search engines in a wide variety of situations," said Meredith Abreu Ressi, Vice President of Research at Manhattan Research. "Companies should tailor keywords, landing pages, and conversion points to be relevant to a variety of stages along the disease continuum. It's also important for brand teams to take note of search behavior variations between demographic and condition groups when creating a targeted pharma search engine marketing campaign."

In addition to an analysis of situations in which consumers use search engines, the study looks at search terms used by consumers, factors contributing to perceived trust of search results, and consumer use of paid versus organic search results.

About ePharma Consumer® v8.0
ePharma Consumer® v8.0 is Manhattan Research's market research and strategic advisory service focused on consumers online for pharmaceutical information. In addition to the use of search engines for health and pharma information, ePharma Consumer® covers the impact of social networking/Web 2.0 and tracks consumer interaction with more than 250 branded and unbranded pharmaceutical sites, including in-depth data on the effect of DTC advertising, visitation, site search rationales, desired site tools and features, and actions taken off-site.

ePharma Consumer® v8.0 was conducted via online survey in Q4 2008 among 6,566 adults (age 18+). Overall market research can be segmented for over 85 condition groups. For additional product and subscription information, please visit http://www.manhattanresearch.com/products/Strategic_Advisory/ePC/

Some of the product sites covered in ePharma Consumer® include Abilify, Aciphex, Actonel, Advair, Ambien/Ambien CR, Aranesp, Aricept, Boniva, Botox, Caduet, Chantix, Cialis, Concerta, Copaxone, Crestor, Cymbalta, Depakote, Depo-Provera, Detrol LA, Effexor XR, Enbrel, Flomax, Flonase, Flovent, Fosamax, Gardasil, Humira, Imitrex, Lamisil, Lantus, Lexapro, Levitra, Lipitor, Lunesta, Nasacort, Nasonex, Neulasta, Neurontin, Nexium, Norvasc, NuvaRing, Ortho Evra, Ortho Tri-Cyclen Lo, Paxil, Plavix, Pravachol, Prevacid, Protonix, Provigil, Pulmicort, Rebif, Remicade, Restasis, Risperdal, Rozerem, Seasonale, Seroquel, Singulair, Strattera, Tamiflu, Topamax, Toprol XL, TriCor, Valtrex, Viagra, Vytorin, Wellbutrin XL, Yasmin, Yaz, Zetia, Zocor, Zoloft, Zomig, and Zyprexa.

About Manhattan Research
Manhattan Research, a Decision Resources, Inc. company, is a leading market research and advisory services firm for global pharmaceutical and healthcare companies. For more information, visit http://www.manhattanresearch.com.

About Decision Resources, Inc.
Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at http://www.decisionresourcesinc.com.

Most Popular Now

Johnson & Johnson announces advance purchase a…

Janssen Pharmaceutica NV, one of the Janssen Pharmaceutical Companies of Johnson & Johnson (NYSE: JNJ) (the Company), has entered into an agreement with the African Vacci...

Pfizer and BioNTech confirm high efficacy and no s…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced updated topline results from analysis of 927 confirmed symptomatic cases of COVID-19 observed in their pi...

Pfizer-BioNTech announce positive topline results …

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that, in a Phase 3 trial in adolescents 12 to 15 years of age with or without prior evidence of SAR...

GSK to support manufacture of Novavax' COVID-19 va…

GSK has reached an agreement in principle with Novavax and the UK Government Vaccines Taskforce to support manufacturing of up to 60 million doses of Novavax' COVID-19 va...

Valneva reports positive Phase 1/2 data for its in…

Valneva SE, a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical n...

Clinical trial completion rates decline during COV…

Social distancing and lockdowns may have reduced the spread of COVID-19, but researchers from Penn State College of Medicine also report those actions may have affected c...

BioNTech provides update on vaccine production sta…

BioNTech SE today announced that the European Medicines Agency (EMA) approved the manufacturing of the COVID-19 vaccine drug product at the facility in Marburg. As part o...

COVID-19 convalescent plasma with greater antibody…

Convalescent plasma, the use of survivors' antibodies transfused into sick COVID-19 patients is safe and significantly improves clinical outcomes when using high levels o...

Pfizer and BioNTech request regulatory agencies ex…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today requested amendments to the U.S. Emergency Use Authorization (EUA) of the Pfizer-BioNTech vaccine (BNT162b2) ...

COVID-19 causes 'unexpected' cellular response in …

New insights into the immune response to SARS-CoV-2 infections could bring better treatments for COVID-19 cases. An international team of researchers unexpectedly foun...

Study identifies possible COVID-19 drugs - includi…

A team led by scientists in the Perelman School of Medicine at the University of Pennsylvania has identified nine potential new COVID-19 treatments, including three that ...

Undetected coronavirus variant was in at least 15 …

A highly contagious SARS-CoV-2 variant was unknowingly spreading for months in the United States by October 2020, according to a new study from researchers with The Unive...